SCHEMBL3607948

SCHEMBL3607948

CN(CCNC(=O)Cn1ncc2c(Cl)nccc21)C1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
MITF O75030 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
MDM2 Q00987 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
ATM Q13315 1/20 0.39
TP53 P04637 2/20 0.38
MEN1 O00255 3/20 0.37
THRB P10828 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
PIK3CA P42336 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607944 0.83 HTT (0.50) KMT2AMAPTLMNAMITFRAB9A
SCHEMBL3585647 0.82 ATM (0.43) KMT2AMAPTLMNAMITFRAB9A
SCHEMBL3591608 0.80 BCHE (0.43) KMT2AMAPTSMN1; SMN2BCHEACHE
SCHEMBL3602593 0.80 TSHR (0.57) KMT2AMAPTRAB9ARECQLSMN1; SMN2
SCHEMBL3591241 0.78 CHEK1 (0.41) KMT2AMAPTSMN1; SMN2BCHEACHE
SCHEMBL3603709 0.77 KMO (0.43) KMT2AMAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL3591258 0.75 MAPK1 (0.45) KMT2AMAPTRAB9ASMN1; SMN2BCHE
SCHEMBL13115698 0.75 GABRP (0.40) KMT2AMAPTLMNAMITFRAB9A
SCHEMBL3586854 0.75 KDM4E (0.42) KMT2ARAB9AALDH1A1SMN1; SMN2ATM
SCHEMBL3179824 0.75 HBB (0.57) MAPTALDH1A1SMN1; SMN2TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KMT2A 3838/4885MAPT 2809/4885LMNA 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.